Browse > Article
http://dx.doi.org/10.3344/kjp.2009.22.1.74

Implantable Intrathecal Drug Delivery Pump in Complex Regional Pain Syndrome Patient -A case report-  

Seo, Kyung Soo (Department of Anesthesiology and Pain Medicine, Ajou University Hospital, College of Medicine, Ajou University)
Han, Kyung Ream (Department of Anesthesiology and Pain Medicine, Ajou University Hospital, College of Medicine, Ajou University)
Kim, Sae Young (Pain Clinic, CHA General Hospital, College of Medicine, Pochon CHA University)
Park, Kyeong Eon (Department of Anesthesiology and Pain Medicine, Ajou University Hospital, College of Medicine, Ajou University)
Kim, Chan (Department of Anesthesiology and Pain Medicine, Ajou University Hospital, College of Medicine, Ajou University)
Publication Information
The Korean Journal of Pain / v.22, no.1, 2009 , pp. 74-77 More about this Journal
Abstract
Implantable intrathecal pump is one of the therapeutic options for intractable pain. A 24-year-old male with complex regional pain syndrome was suffering from right lower extremity pain. He had all modalities of treatment including spinal cord stimulator. However, his pain had been worse in the past 6 months. His visual analogue pain scale (VAS) was 8-10 and he could not sit or walk. Only opioid was thought to be effective. Then, intrathecal pump was considered. We estimated the minimal effective dose of spinal morphine before implantation. 0.3 mg of morphine was injected intrathecally as a starting dose. Dosage had been increased up to 0.8 mg in 10 days. His VAS score decreased from 8 to 5. He could sleep without pain and walk with crutch. Therefore, intrathecal pump was inserted. He could tolerate to pain. This case suggests that intrathecal morphine delivery can provide effective treatment for intractable non-malignant pain.
Keywords
complex regional pain syndrome; implantable pump; intrathecal morphine;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Pert CB, Snyder SH: Opiate receptor: demonstration in nervous tissue. Science 1973; 179: 1011-4   DOI   PUBMED   ScienceOn
2 Koulousakis A, Kuchta J, Bayarassou A, Sturm V: Intrathecal opioids for intractable pain syndromes. Acta Neurochir Suppl 2007; 97: 43-8
3 Hassenbusch SJ: Epidural and subarachnoid administration of opioids for nonmalignant pain: technical issues, current approaches and novel treatments. J Pain Symptom Manage 1996; 11: 357-62   DOI   PUBMED   ScienceOn
4 Bejjani GK, Karim NO, Tzortzidis F: Intrathecal granuloma after implantation of a morphine pump: case report and review of the literature. Surg Neurol 1997; 48: 288-91   DOI   ScienceOn
5 Hassenbusch SJ, Paice JA, Patt RB, Bedder MD, Bell GK:Clinical realities and economic considerations: economics of intrathecal therapy. J Pain Symptom Manage 1997; 14 (Suppl 3): 36-48   DOI   ScienceOn
6 Simpson RK Jr: Mechanisms of action of intrathecal medications. Neurosurg Clin N Am 2003; 14: 353-64   DOI   PUBMED   ScienceOn
7 Belverud S, Mogilner A, Schulder M: Intrathecal pumps. Neurotherapeutics 2008; 5: 114-22   DOI   ScienceOn
8 Sylvester RK, Lindsay SM, Schauer C: The conversion challenge: from intrathecal to oral morphine. Am J Hosp Palliat Care 2004; 21: 143-7   DOI   ScienceOn
9 Krames ES: Intraspinal opioid therapy for chronic nonmalignant pain: current practice and clinical guidelines. J Pain Symptom Manage 1996; 11: 333-52   DOI   PUBMED   ScienceOn
10 Chaney MA: Side effects of intrathecal and epidural opioids. Can J Anaesth 1995; 42: 891-903   DOI   ScienceOn
11 Burton AW, Rajagopal A, Shah HN, Mendoza T, Cleeland C, Hassenbusch SJ 3rd, et al: Epidural and intrathecal analgesia is effective in treating refractory cancer pain. Pain Med 2004; 5: 239-47   DOI   ScienceOn
12 Baron R: Complex regional pain syndromes. In: Wall and Melzack's textbook of pain. 5th ed. Edited by MacMahon SB, Koltzenburg M: Philadelpia, PA, Elsevier Churchill Livingstone. 2006, pp 1011-27
13 Kumar K, Kelly M, Pirlot T: Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology:long-term benefits and efficacy. Surg Neurol 2001; 55:79-86   DOI   ScienceOn
14 Ruan X: Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician 2007; 10: 357-66   PUBMED   ScienceOn
15 Krames ES, Lanning RM: Intrathecal infusional analgesia for nonmalignant pain: analgesic efficacy of intrathecal opioid with or without bupivacaine. J Pain Symptom Manage 1993; 8: 539-48   DOI   ScienceOn
16 Galer BS, Schwarz L, Allen RJ: Complex regional pain syndromes-type I: Reflex sympathetic dystrophy, and type II: Causalgia. In: Bonica's management of pain. 3rd ed. Edited by John D, Loeser MD: Philadelphia, PA, Lippincott Williams & Wilkins. 2001, pp 388-411
17 Jacobson L, Chabal C, Brody MC: A dose-response study of intrathecal morphine: efficacy, duration, optimal dose, and side effects. Anesth Analg 1988; 67: 1082-8   DOI   PUBMED   ScienceOn
18 Gilmer-Hill HS, Boggan JE, Smith KA, Wagner FC Jr:Intrathecal morphine delivered via subcutaneous pump for intractable cancer pain: a review of the literature. Surg Neurol 1999; 51: 12-5   DOI   ScienceOn